Once inside the cell, they are activated by a series of intracellular phosphorylation steps to produce 5′-triphosphate derivatives. In many cases, nucleoside analogues are poor substrates for the cellular kinases needed for their activation. It is clear that intracellular introduction of nucleoside analogues as phosphorylated metabolites (so called pronucleotides) could circumvent difficulties associated with the use of non-phosphorylated nucleoside analogues. Methods: Among the current diverse pronucleotide approaches, nucleoside phosphoramidate derivatives appear to be an interesting class of potential antiviral agents because of the known relatively low stability of the P-N bond in cellular media. On the basis of oxathiaphospholane chemistry, a series of novel conjugates of 5′-O-phosphorylated zidovudine (AZT) and stavudine (d4T) with amino acids carboxamidates were obtained. N-(2-thiono-1,3,2 
Since the recognition of the first HIV/AIDS case >25 years ago, a number of emerging and re-emerging infectious diseases of humans and animals have been reported, including severe acute respiratory syndrome, avian flu, West Nile fever and Ebola [1] . Interestingly, all these infectious diseases are caused by viral infections and, in particular, RNA viruses.
With the elucidation of virus-specific events that can be used as chemotherapeutic targets, selective treatment can be achieved and virus replication can be suppressed without deleterious effects on the host. Any of the steps involved in the viral replication cycle could potentially be targets for chemotherapeutic intervention [2] .
Notably, viral polymerases appear to be one of the most promising targets for antivirals against viruses that utilize their own polymerases for replication. For example, the HIV type-1 (HIV-1)-encoded reverse transcriptase is a promising target because human cells lack RNA-dependent DNA polymerase activity. Other viruses might also code for their own polymerases, such as the RNA-dependent RNA polymerase of flaviviruses [3] . Therefore, it is not surprising that out of the >30 compounds that are currently marketed in the US for treatment of viral infections, 15 are polymerase inhibitors, most of which are nucleoside analogues [4] . Among them, ribavirin is a particularly important drug that possesses broad-spectrum antiviral activity against several RNA and DNA viruses [5] . It should be noted that ribavirin might have several mechanisms of action. Ribavirin is phosphorylated by cellular adenosine kinase to ribavirin-5′-monophosphate, which is a potent inhibitor of inosine monophosphate (IMP) Introduction dehydrogenase, resulting in a decrease of cellular GTP pools and inhibition of viral RNA synthesis [6] . However, it is also an effective inhibitor of viral RNA guanylyl transferase and (guanine-7N)-methyl transferase, which results in a defective 5′-cap structure of viral transcripts and insufficient translation. The 5′-triphosphate form of ribavirin has been implicated as a direct inhibitor of the viral RNA polymerase. Because it is a nucleotide analogue, ribavirin-5′-triphosphate, the major metabolite accumulating in vivo [7] , can also be incorporated into the viral genome, inducing an error catastrophe that will result in the accumulation of mutations in the viral genome (for example, polio virus) [8] . Ribavirin, in combination with pegylated interferon, has become the standard therapy for the treatment of HCV infections [9] .
In many cases, nucleoside analogues are poor substrates for the cellular kinases needed for their activation [10] . Also, the presence and activity of the intracellular enzymes necessary for activation of nucleoside analogues are highly dependent on the host species, the cell type and the stage of the cell cycle. It is worth noting that among the three successive activating phosphorylation steps, the first step that is responsible for formation of the nucleoside analogue monophosphate is often regarded as the bottleneck, although, in other cases, the second phosphorylation step can also be rate-limiting (for example, conversion of AZT [zidovudine] monophosphate to AZT diphosphate) [11, 12] . It is thus clear that intracellular introduction of nucleoside analogues as phosphorylated metabolites could circumvent difficulties associated with the use of non-phosphorylated nucleoside analogues and could even activate inactive compounds or could increase the activity of the nucleoside analogues. However, polarity (hydrophilicity) and a ready degradation by phosphatases make the use of free nucleotide analogues impractical. Therefore, much of the recent efforts have been focused on finding suitable prodrugs of nucleoside analogue monophosphates (pronucleotides) and a number of pronucleotide approaches have been developed [13] [14] [15] [16] . In general, these methods rely on remote chemical or enzymatic activation of the masking moiety, followed by degradation of an unstable intermediate and release of the nucleotide [17] .
Among the current diverse prodrug approaches, nucleoside phosphoramidate derivatives appear to be an interesting class of antiviral agents [13, 16] . In several cases, these compounds exhibited enhanced antiviral activity and reduced cytotoxicity when compared with the parent nucleoside [18] . Recently, Iyer et al. [19] demonstrated that nucleoside amino acid phosphoramidate monoesters, despite carrying one formal charge on the phosphate moiety, fulfill requirements of lipophilicity for passive diffusion through the membrane barrier and non-toxicity after hydrolytic or enzymatic release in the target cell. For example, corresponding AZT derivatives were less lipophilic than AZT (logP=0.24), with logP values ranging from -0.8 to -1.8.
We recently described a new approach to the preparation of O-alkyl-N-acylphosphoramidothioates and corresponding phosphoramidates [20] . This method relies upon oxathiaphospholane chemistry, which we have found to be applicable to the synthesis of a wide variety of organophosphorus compounds [21] . On the basis of these results, the goal of this study was to synthesize a series of conjugates of 5′-O-phosphorylated antiviral nucleosides with amino acid carboxamidates. To our knowledge, O-alkyl-N-acylphosphoramidates have not been tested as potential prodrugs, and their synthesis are of interest because of the known relatively low stability of the P-N bond in cellular media. Although the enzyme responsible for hydrolysis of the P-N bond in phosphoramidates has not been established [22] , involvement of putative phosphoramidase (Hint-1) in the intracellular release of nucleoside 5′-Ophosphate has been demonstrated [23] . 
Methods
General procedure for the synthesis of N-(2-thiono-1,3,2-oxathiaphospholanyl)amino acid carboxamides
To a solution of amino acid carboxamide 1a-d (1 mmol; Bachem AG, Bubendorf, Switzerland) in 5 ml of dry pyridine, elemental sulfur (2 mmol; Sigma-Aldrich, St Louis, MO, USA) was added and then 2-chloro-1,3,2oxathiaphospholane (2; 1 mmol [21] ) was added dropwise. The reaction mixture was stirred at room temperature for 12 h. The solvent was then removed under reduced pressure and acetonitrile (10 ml) was added to the residue, and an excess of sulfur was filtered off. After evaporation of the solvent under reduced pressure, the residue was dissolved in 2-3 ml of chloroform and applied to a silica gel column (2.5×18 cm; SiO 2 ; Merck, Darmstadt, Germany). The column was washed with methanol in chloroform (from 0 to 5%). Appropriate fractions were combined and evaporated under reduced pressure providing the desired compounds as a mixture of two diastereoisomers (3a-d; Figure 1 ). Their chemical shift values ( 31 P NMR) and fast atom bombardment mass spectrometry (FAB-MS) are summarized in Table 1 .
General procedure for the synthesis of nucleoside N-acylphosphoramidates
Corresponding compound 3a-d (1 mmol) were dissolved in dry acetonitrile (10 ml) and to this solution, AZT (3′-azido-3′-deoxythymidine; 4; Tokyo Chemical Industry Co. Ltd, Tokyo, Japan) or stavudine (3′-deoxy-2′,3′-didehydrothymidine; d4T; 5; 2 mmol; Tokyo Chemical Industry Co. Ltd) was added followed by 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU; 1.2 mmol; Sigma-Aldrich). The reaction mixture was stirred for 3 h at room temperature and then concentrated under reduced pressure. For removal of trityl protecting group, compound 7d was treated with Dowex H + 200-400 mesh (SERVA, Heidelberg, Germany). Compounds 6-7 were isolated using ionexchange chromatography (DEAE Sephadex A-25; Pharmacia, Stockholm, Sweden) with triethylammonium bicarbonate (TEAB; from 0.0 to 0.1 M; pH 7.5; triethylamine; Sigma-Aldrich) as the eluent. Compounds 6-7 (1 mmol) were then dissolved in water (2 ml) and PhIO 2 (2 mmol) was added to this solution. The obtained suspension was stirred for 2 h at room temperature and then concentrated under reduced pressure. Compounds 8-9 ( Figure 2 isolated using ion-exchange chromatography (DEAE-Sephadex A-25) with TEAB (from 0.0 to 0.1 M; pH 7.5) as the eluent. 
Antiviral and cytotoxic activity assays
The antiviral assays (with the exception of anti-HIV-1 assays) were based on the inhibition of virus-induced cytopathic effect in HEL (herpes simplex virus type- 
Results

Chemistry
A series of conjugates of 5′-O-phosphorylated AZT and d4T with amino acids carboxamidates were obtained. The synthesis was performed based on oxathiaphospholane chemistry using N-(2-thiono-1,3,2-oxathiaphospholane) derivatives of amino acids carboxamides (3a-d) as precursors. These intermediates were easily produced with a yield in the range of 40-69%, and were stable compounds that could be stored for a long time. The oxathiaphospholane derivatives of compound 3 were considered as intermediates for the condensation reaction with compound 4 and compound 5. This reaction, based on DBU-assisted nucleophilic attack of the hydroxyl group of 4 or 5 on the phosphorus atom of the oxathiaphospholane ring in 3, provided the phosphorothioate derivatives 6 and 7 after 12 h.
These compounds, which are key intermediates in the synthesis of nucleoside 5′-O-(N-acyl)phosphoramidates, were obtained in low yield (23-56%) because the DBU-assisted condensation reaction that provided these compounds was accompanied by the production of the by-product diazophospholane-type (compound 10; Figure 3 ). The structure of 10 was determined by 1 H and 31 P NMR and FAB-MS spectra. This compound resulted from the withdrawing of the amidic proton from oxathiaphospholane derivative 3 in the presence of DBU and subsequent intramolecular cyclization.
After isolation by ion-exchange chromatography, compounds 6 and 7 were oxidized to 8 and 9, respectively, by treatment with iodoxybenzene. On the basis of previous data (RK, unpublished observations) on the transformation of O-alkyl-N-acylphosphoramidothioates into corresponding phosphoramidates, tert-butylperoxytrimethylsilane was used; however, the application of iodoxybenzene as an oxidizing reagent was found to be more efficient. The time needed for transformation of compounds 6 and 7 into 8 and 9, respectively, was also different: 1 h for alanine derivatives, 4 h for phenylalanine derivatives and 18 h for prolinamide derivatives (examination of the reaction mixture by 31 P NMR).
The final products 8 and 9 were isolated by ionexchange chromatography with a 43-95% yield (calculated based on the oxidation step) and their structures were confirmed by 31 P NMR and FAB-MS analyses.
Virology
Results on the virological assays can be found in Tables  2, 3 
Discussion
Both the d4T and the AZT prodrugs markedly inhibited HIV-1 and HIV-2 replication in MT-4 cell cultures at compound concentrations that were equally active or inferior to the activity of their parental free nucleosides (2-to 20-fold for the AZT prodrugs and 6-to 40-fold for the d4T prodrugs). The pronounced antiviral activity noticed in the MT-4 cell cultures was also confirmed for HIV-1 in PBMCs, in which the EC 50 values were even more pronounced than those found in the MT-4 cell cultures ( Table 2 ). The compounds were also evaluated for their anti-HIV activity in CEM and in CEM thymidine-kinase-deficient (CEM/TK -) cell cultures. They substantially lost antiviral potency in the CEM/TKcells, suggesting an eventual conversion of the test compounds to the free nucleoside prior to further phosphorylation to the active 5′-triphosphate metabolite.
Unfortunately none of the tested compounds showed antiviral activity against a broad range of DNA and RNA viruses at subtoxic concentrations, except for HIV-1 and HIV-2 (Tables 2, 3, 4, 5 and 6).
It would now be interesting to investigate whether the d4T and AZT prodrugs have more favourable pharmacokinetics compared with the parent drugs in vivo. Also, it would be worth synthesizing similar types of nucleotide prodrugs containing other bases, such as cytosine or (substituted) purines.
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